EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ticagrelor and gut microbiota: Absence of pharmacokinetic interaction in vitro and in vivo studies

Pan Qu, Yongchao Gao, Xiaojie Li, Li Yang, Jie Tang, Manyun Chen, Yicheng Wang, Yilei Peng, Junyi Jiang, Weihua Huang, Wei Zhang, Yali Liu und 1 weitere

PLOS One · 2026

DOI: 10.1371/journal.pone.0359660 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2026. Verfasst von Pan Qu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Engineering Research Center of Applied Technology of Pharmacogenomics (Ministry of Education, China), Hunan Key Laboratory of Pharmacomicrobiomics, D…. Hauptthemen laut MEDLINE: Adenosine, Gastrointestinal Microbiome, Platelet Aggregation Inhibitors. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, the scientific research project of Furong laboratory of Central South University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ticagrelor, a commonly used antiplatelet medication, has been found to exhibit considerable inter-individual pharmacodynamic variability. Recent studies have revealed a close relationship between pharmacokinetics and pharmacodynamics, both of which can be influenced by gut microbiota. In this study, we explored whether the pharmacokinetics of ticagrelor is mediated by intestinal flora. We enrolled 22 healthy participants to assess the clinical pharmacokinetic profiles of ticagrelor and its metabolite AR-C124910XX after a single oral dose of ticagrelor. The fecal microbial compositions of individuals who exhibited distinct pharmacokinetic parameters were analyzed using 16S rRNA gene sequencing. Additionally, we conducted experiments involving the co-incubation of ticagrelor with fecal bacteria and a systematic exploration of the pharmacokinetics of ticagrelor in pseudo-germ-free (PGF) rats to illustrate the role of gut microbiota in ticagrelor metabolism, both in vitro and in vivo . Our findings revealed a three-fold difference in the bioavailability of ticagrelor among individuals. However, no difference was found in the composition of gut microbiota among individuals with different pharmacokinetic parameters. Quantitative analysis showed that gut microbiota cannot directly metabolize ticagrelor. Furthermore, there were no significant differences in AUC (0–48) , AUC (0-∞), and C max between ticagrelor and AR-C124910XX in PGF rats compared to normal control, either by single intragastric or intravenous administration. In conclusion, these findings suggest that gut microbiota has no impact on the pharmacokinetics of ticagrelor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdenosineGastrointestinal MicrobiomePlatelet Aggregation InhibitorsTicagrelorHumansAnimalsRatsMaleAdultRNA, Ribosomal, 16SFecesFemaleYoung AdultAdministration, OralPurinergic P2Y Receptor AntagonistsRats, Sprague-Dawley

Substanzen

TicagrelorAdenosineAR C124910XXRNA, Ribosomal, 16SPlatelet Aggregation InhibitorsPurinergic P2Y Receptor Antagonists

Autor:innen und Institutionen

  • Engineering Research Center of Applied Technology of Pharmacogenomics (Ministry of Education, China), Hunan Key Laboratory of Pharmacomicrobiomics, Department of Clinical Pharmacology, Xiangya Hospital, Central South Un…
  • Department of Pharmacy, Hunan Prevention and Treatment Institute for Occupational Diseases, Affiliated Prevention and Treatment Institute for Occupational Diseases of University of South China, Changsha, China.
  • The First Affiliated Hospital of Shantou University Medical College, Shantou, China.
  • Department of Pharmacy, Hunan Provincial People's Hospital, the First Affiliated Hospital of Hunan Normal University, Changsha, China.
  • Department of Cardiovascular, Xiangya Hospital, Central South University, Changsha, China.

ORCID-Profile: Yali Ou

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • the scientific research project of Furong laboratory of Central South University
  • Natural Science Foundation of Hunan Province

Zitieren

APA

Qu, P., Gao, Y., Li, X., Yang, L., Tang, J., Chen, M., Wang, Y., Peng, Y., Jiang, J., Huang, W., Zhang, W., Liu, Y., & Ou, Y. (2026). Ticagrelor and gut microbiota: Absence of pharmacokinetic interaction in vitro and in vivo studies. PLOS One. https://doi.org/10.1371/journal.pone.0359660

Vancouver

Qu P, Gao Y, Li X, Yang L, Tang J, Chen M, et al. Ticagrelor and gut microbiota: Absence of pharmacokinetic interaction in vitro and in vivo studies. PLOS One. 2026. doi:10.1371/journal.pone.0359660

BibTeX
@article{Qu2026,
  author = {Qu, Pan and Gao, Yongchao and Li, Xiaojie and Yang, Li and Tang, Jie and Chen, Manyun and Wang, Yicheng and Peng, Yilei and Jiang, Junyi and Huang, Weihua and Zhang, Wei and Liu, Yali and Ou, Yali},
  title = {Ticagrelor and gut microbiota: Absence of pharmacokinetic interaction in vitro and in vivo studies},
  journal = {PLOS One},
  year = {2026},
  doi = {10.1371/journal.pone.0359660}
}
Kostenlos starten →